PMID- 34970150
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240405
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Mechanisms Underlying the Antidiabetic Activities of Polyphenolic Compounds: A 
      Review.
PG  - 798329
LID - 10.3389/fphar.2021.798329 [doi]
LID - 798329
AB  - Polyphenolic compounds are thought to show considerable promise for the treatment 
      of various metabolic disorders, including type 2 diabetes mellitus (T2DM). This 
      review addresses evidence from in vitro, in vivo, and clinical studies for the 
      antidiabetic effects of certain polyphenolic compounds. We focus on the role of 
      cytotoxic human amylin (hA) aggregates in the pathogenesis of T2DM, and how 
      polyphenols can ameliorate this process by suppressing or modifying their 
      formation. Small, soluble amylin oligomers elicit cytotoxicity in pancreatic 
      islet beta-cells and may thus cause beta-cell disruption in T2DM. Amylin oligomers may 
      also contribute to oxidative stress and inflammation that lead to the triggering 
      of beta-cell apoptosis. Polyphenols may exert antidiabetic effects via their ability 
      to inhibit hA aggregation, and to modulate oxidative stress, inflammation, and 
      other pathways that are beta-cell-protective or insulin-sensitizing. There is 
      evidence that their ability to inhibit and destabilize self-assembly by hA 
      requires aromatic molecular structures that bind to misfolding monomers or 
      oligomers, coupled with adjacent hydroxyl groups present on single phenyl rings. 
      Thus, these multifunctional compounds have the potential to be effective against 
      the pleiotropic mechanisms of T2DM. However, substantial further research will be 
      required before it can be determined whether a polyphenol-based molecular entity 
      can be used as a therapeutic for type 2 diabetes.
CI  - Copyright (c) 2021 Nie and Cooper.
FAU - Nie, Tina
AU  - Nie T
AD  - School of Biological Sciences, Faculty of Science, the University of Auckland, 
      Auckland, New Zealand.
FAU - Cooper, Garth J S
AU  - Cooper GJS
AD  - School of Biological Sciences, Faculty of Science, the University of Auckland, 
      Auckland, New Zealand.
AD  - The Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, the 
      University of Auckland, Auckland, New Zealand.
AD  - Centre for Advanced Discovery and Experimental Therapeutics, Division of 
      Cardiovascular Sciences, Faculty of Biology Medicine & Health, School of Medical 
      Sciences, The University of Manchester, Manchester, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211214
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8712966
OTO - NOTNLM
OT  - IAPP
OT  - amylin
OT  - flavonoids
OT  - insulin
OT  - islet beta-cells
OT  - natural products
OT  - polyphenol
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/01 06:00
MHDA- 2022/01/01 06:01
PMCR- 2021/12/14
CRDT- 2021/12/31 06:02
PHST- 2021/10/20 00:00 [received]
PHST- 2021/11/18 00:00 [accepted]
PHST- 2021/12/31 06:02 [entrez]
PHST- 2022/01/01 06:00 [pubmed]
PHST- 2022/01/01 06:01 [medline]
PHST- 2021/12/14 00:00 [pmc-release]
AID - 798329 [pii]
AID - 10.3389/fphar.2021.798329 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Dec 14;12:798329. doi: 10.3389/fphar.2021.798329. 
      eCollection 2021.